Upcoming Events

The Tripe Club of Victoria is delighted to present Dr Peter Molloy, a scientist-entrepreneur who has been involved in various aspects of medical science for over 40yrs. He holds a Bachelor of Science degree in Microbiology and Biochemistry, an MBA and a PhD in biotechnology business.

​

Early in his career, Dr Molloy, as a senior executive, managed a number of businesses in the international pharmaceutical industry and lived in the United States for some 15 years, in addition to working in Australia at various times. He is widely known in Australia as the person behind the Betadine range of topical antiseptics and as the creator of the “Betadine Sore Throat Gargle”.

​

Following his departure from the pharmaceutical industry, Peter was appointed as the CEO of several biotechnology companies, including three that were listed on the ASX. One of these was Biota Ltd (antiviral research company) that has developed treatments for respiratory viral diseases, such as influenza, RSV, and the common cold. Indeed, his principal research- interest for the last 20 years has been in the field of respiratory viral diseases.

​

In 2012, he established the company, Firebrick Pharma,that listed on the ASX in 2022. Firebrick’s ambitious mission was to create a nasal spray to combat certain viruses and in particular, as a treatment for the common cold. Peter was the lead inventor on the company’s patented technology, as well as a second patent, covering its use as a preventative for pandemic viral diseases, including: pandemic flu, Ebola and coronavirus diseases, notably COVID-19.